

SAFETY DATA SHEET



Temozolomide Injection Formulation

Version 16.1 Revision Date: 2025/04/14 SDS Number: 27571-00030 Date of last issue: 2024/12/18 Date of first issue: 2014/11/03

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Temozolomide Injection Formulation

Supplier's company name, address and phone number

Company name of supplier : MSD

Address : Kumagaya, Saitama Prefecture , Xicheng 810 MSD Co., Ltd.
Menuma factory

Telephone : 048-588-8411

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS classification of chemical product

Serious eye damage/eye irritation : Category 2A

Germ cell mutagenicity : Category 2

Carcinogenicity : Category 2

Reproductive toxicity : Category 1B

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Bone marrow, thymus gland, Lymph nodes, spleen)

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H319 Causes serious eye irritation.
H341 Suspected of causing genetic defects.
H351 Suspected of causing cancer.
H360FD May damage fertility. May damage the unborn child.

SAFETY DATA SHEET



Temozolomide Injection Formulation

Version 16.1	Revision Date: 2025/04/14	SDS Number: 27571-00030	Date of last issue: 2024/12/18 Date of first issue: 2014/11/03
-----------------	------------------------------	----------------------------	---

H373 May cause damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure if swallowed.

Precautionary statements

: **Prevention:**

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P264 Wash skin thoroughly after handling.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P337 + P313 If eye irritation persists: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Important symptoms and outlines of the emergency assumed : Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Citric acid	77-92-9	>= 10 - < 20	2-1318
Temozolomide	85622-93-1	>= 1 - < 10	

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical

SAFETY DATA SHEET



Temozolomide Injection Formulation

Version 16.1	Revision Date: 2025/04/14	SDS Number: 27571-00030	Date of last issue: 2024/12/18 Date of first issue: 2014/11/03
-----------------	------------------------------	----------------------------	---

	advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: Contact with dust can cause mechanical irritation or drying of the skin. Causes serious eye irritation. Suspected of causing genetic defects. Suspected of causing cancer. May damage fertility. May damage the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Nitrogen oxides (NO _x) Metal oxides Chlorine compounds
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do

SAFETY DATA SHEET



Temozolomide Injection Formulation

Version
16.1

Revision Date:
2025/04/14

SDS Number:
27571-00030

Date of last issue: 2024/12/18
Date of first issue: 2014/11/03

so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation

: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling

: Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

SAFETY DATA SHEET



Temozolomide Injection Formulation

Version 16.1	Revision Date: 2025/04/14	SDS Number: 27571-00030	Date of last issue: 2024/12/18 Date of first issue: 2014/11/03
-----------------	------------------------------	----------------------------	---

Avoidance of contact Hygiene measures	Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment. : Oxidizing agents : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
Storage	
Conditions for safe storage	: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types: Strong oxidizing agents
Packaging material	: Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Threshold limit value and permissible exposure limits for each component in the work environment

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Concentra- tion standard / Permissible con- centration	Basis
Temozolomide	85622-93-1	TWA	0.1 ug/m ³ (OEB 5)	Internal
		Wipe limit	1 µg/100 cm ²	Internal

Engineering measures	: The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation
-----------------------------	--

Temozolomide Injection Formulation

Version 16.1	Revision Date: 2025/04/14	SDS Number: 27571-00030	Date of last issue: 2024/12/18 Date of first issue: 2014/11/03
-----------------	------------------------------	----------------------------	---

(e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Particulates type
Hand protection	
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state	: powder
Colour	: white
Odour	: No data available
Odour Threshold	: No data available
Melting point/freezing point	: No data available

SAFETY DATA SHEET



Temozolomide Injection Formulation

Version 16.1 Revision Date: 2025/04/14 SDS Number: 27571-00030 Date of last issue: 2024/12/18
Date of first issue: 2014/11/03

Boiling point, initial boiling point and boiling range : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Lower explosion limit and upper explosion limit / flammability limit

Upper explosion limit / Up- per flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : Not applicable

Decomposition temperature : No data available

pH : No data available

Evaporation rate : Not applicable

Auto-ignition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Solubility(ies)

Water solubility : soluble

Partition coefficient: n-octanol/water : Not applicable

Vapour pressure : Not applicable

Density and / or relative density

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

SAFETY DATA SHEET



Temozolomide Injection Formulation

Version 16.1 Revision Date: 2025/04/14 SDS Number: 27571-00030 Date of last issue: 2024/12/18
Date of first issue: 2014/11/03

Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg
Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Temozolomide:

Acute oral toxicity : LD50 (Dog): 19 mg/kg
LD50 (Rat): 315 mg/kg
LD50 (Mouse): 205 mg/kg

Temozolomide Injection FormulationVersion
16.1Revision Date:
2025/04/14SDS Number:
27571-00030Date of last issue: 2024/12/18
Date of first issue: 2014/11/03**Skin corrosion/irritation**

Not classified based on available information.

Components:**Citric acid:**

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:**Citric acid:**

Species : Rabbit
Result : Irritation to eyes, reversing within 21 days
Method : OECD Test Guideline 405

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Temozolomide:**

Test Type : Maximisation Test
Exposure routes : Dermal
Species : Guinea pig
Result : negative

Germ cell mutagenicity

Suspected of causing genetic defects.

Components:**Citric acid:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: in vitro micronucleus test
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

Temozolomide Injection Formulation

Version 16.1	Revision Date: 2025/04/14	SDS Number: 27571-00030	Date of last issue: 2024/12/18 Date of first issue: 2014/11/03
-----------------	------------------------------	----------------------------	---

cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Temozolomide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: positive

Test Type: Chromosome aberration test in vitro
Test system: Human lymphocytes
Result: positive

Germ cell mutagenicity - Assessment : Positive results from in vitro mammalian mutagenicity assays, chemical structure activity relationship to known germ cell mutagens

Carcinogenicity

Suspected of causing cancer.

Components:**Temozolomide:**

Species : Rat
Application Route : Oral
Exposure time : 6 Months
: 4 mg/kg body weight

Result : positive
Target Organs : Mammary gland

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in animal studies

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:**Citric acid:**

Effects on foetal development : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Temozolomide:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male
Application Route: Oral
Fertility: LOAEL: 8.5 mg/kg body weight
Result: positive

Temozolomide Injection FormulationVersion
16.1Revision Date:
2025/04/14SDS Number:
27571-00030Date of last issue: 2024/12/18
Date of first issue: 2014/11/03

Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Embryo-foetal toxicity: LOAEL: 13 mg/kg body weight Result: positive, Malformations were observed.
Reproductive toxicity - Assessment	: Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

Components:**Citric acid:**

Assessment : May cause respiratory irritation.

STOT - repeated exposure

May cause damage to organs (Bone marrow, thymus gland, Lymph nodes, spleen) through prolonged or repeated exposure if swallowed.

Components:**Temozolomide:**

Exposure routes	: Ingestion
Target Organs	: Bone marrow, thymus gland, Lymph nodes, spleen
Assessment	: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Citric acid:**

Species	: Rat
NOAEL	: 4,000 mg/kg
LOAEL	: 8,000 mg/kg
Application Route	: Ingestion
Exposure time	: 10 Days

Temozolomide:

Species	: Rat, female
NOAEL	: 4 mg/kg
LOAEL	: 21 mg/kg
Application Route	: Oral
Exposure time	: 6 Months
Target Organs	: thymus gland, Bone marrow, Reproductive organs, Lymph nodes
Species	: Rat, male

SAFETY DATA SHEET



Temozolomide Injection Formulation

Version 16.1 Revision Date: 2025/04/14 SDS Number: 27571-00030 Date of last issue: 2024/12/18 Date of first issue: 2014/11/03

NOAEL	:	8.5 mg/kg
LOAEL	:	34 mg/kg
Application Route	:	Oral
Exposure time	:	6 Months
Target Organs	:	thymus gland, Bone marrow, male reproductive organs, Gastrointestinal tract, Lymph nodes
Species	:	Dog
NOAEL	:	2.5 mg/kg
LOAEL	:	6.3 mg/kg
Application Route	:	Oral
Exposure time	:	6 Months
Target Organs	:	Bone marrow, spleen, male reproductive organs, Gastrointestinal tract, thymus gland

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Temozolomide:

Ingestion : Symptoms: Blood disorders, Nausea, Vomiting, Diarrhoea, anorexia, Fatigue, hair loss

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Citric acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,535 mg/l
Exposure time: 24 h

Temozolomide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 90 mg/l

Temozolomide Injection FormulationVersion
16.1Revision Date:
2025/04/14SDS Number:
27571-00030Date of last issue: 2024/12/18
Date of first issue: 2014/11/03

Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 40 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: > 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability**Components:****Citric acid:**

Biodegradability : Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Temozolomide:

Biodegradability : Result: rapidly degradable
Biodegradation: 83 %
Exposure time: 35 d

Stability in water : Degradation half life (DT50): < 1 d

Bioaccumulative potential**Components:****Citric acid:**

Partition coefficient: n-octanol/water : log Pow: -1.72

Temozolomide:

Partition coefficient: n-octanol/water : log Pow: 1.35

Mobility in soil

No data available

Hazardous to the ozone layer

Not applicable

Other adverse effects

No data available

Temozolomide Injection Formulation

Version 16.1 Revision Date: 2025/04/14 SDS Number: 27571-00030 Date of last issue: 2024/12/18
Date of first issue: 2014/11/03

13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo aircraft) : Not applicable
Packing instruction (passenger aircraft) : Not applicable

IMDG-Code

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable
Marine pollutant : Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

Refer to section 15 for specific national regulation.

Special precautions for user

Not applicable

Temozolomide Injection FormulationVersion
16.1Revision Date:
2025/04/14SDS Number:
27571-00030Date of last issue: 2024/12/18
Date of first issue: 2014/11/03

15. REGULATORY INFORMATION**Related Regulations****Fire Service Law**

Not applicable to dangerous materials / designated flammables.

Chemical Substance Control Law

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

Industrial Safety and Health Law**Harmful Substances Prohibited from Manufacture**

Not applicable

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Chemical name
3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide

Substances Subject to be Notified Names

Not applicable

Substances Subject to be Indicated Names

Not applicable

Skin and Eye Damage Substances (ISHL MO Art. 594-2)

Not applicable

Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

SAFETY DATA SHEET



Temozolomide Injection Formulation

Version 16.1 Revision Date: 2025/04/14 SDS Number: 27571-00030 Date of last issue: 2024/12/18
Date of first issue: 2014/11/03

Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Poisonous and Deleterious Substances Control Law

Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Not applicable

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable

Vessel Safety Law

Not regulated as a dangerous good

Aviation Law

Not regulated as a dangerous good

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

Waste Disposal and Public Cleansing Law

Industrial waste

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

SAFETY DATA SHEET



Temozolomide Injection Formulation

Version
16.1

Revision Date:
2025/04/14

SDS Number:
27571-00030

Date of last issue: 2024/12/18
Date of first issue: 2014/11/03

Date format : yyyy/mm/dd

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN